{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:40:17Z","timestamp":1792708817689,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700740"],"award-info":[{"award-number":["81700740"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Irisin is a myokine that leads to increased energy expenditure by stimulating the browning of white adipose tissue. We aimed to investigate the association of serum irisin levels with metabolic parameters in middle aged Chinese population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The study was based on a cross-sectional analysis of data from 524 nondiabetic subjects aged 40~65. All participants were recruited from a screening survey for Metabolic Syndrome in a community in Southwest China, including 294 subjects categorized as overweight (defined as BMI\u226725\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) and 230 subjects as normal control (defined as 18.5\u2266BMI\u2009&lt;\u200925\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ). Serum irisin concentration was quantified by enzyme linked immunosorbent assay (ELISA). The relationship of irisin with metabolic factors was determined by Pearson correlation. Multivariate linear regression was used to analyze the association of irisin with insulin resistance. Logistic regression was performed to assess the association of irisin with odds of overweight.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Serum irisin levels were significantly lower in nondiabetic overweight subjects compared with control (11.46\u2009\u00b1\u20094.11vs14.78\u2009\u00b1\u20097.03\u2009\u03bcg\/mL,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). Circulating irisin was positively correlated with quantitative insulin sensitivity check index (QUICKI,\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.178,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.045) and triglycerides\n                      <jats:italic>(r<\/jats:italic>\n                      \u2009=\u20090.149,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.022); while irisin was negatively correlated with waist circumference (WC,\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.185,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.037), waist-to-hip ratio (WHR,\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.176,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.047), fasting insulin (\n                      <jats:italic>r\u2009=<\/jats:italic>\n                      \u2009\u2212\u20090.2,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.024), serum creatinine (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.243,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006), homeostasis model assessment for insulin resistance (HOMA-IR,\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.189,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.033). Multiple linear regression showed that irisin was inversely associated with HOMA-IR (\u03b2\u2009=\u2009\u2212\u20090.342\u2009\u00b1\u20090.154,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.029). Higher irisin was associated with decreased odds of being overweight (OR\u2009=\u20090.281, \u03b2\u2009=\u2009\u2212\u20091.271,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.024).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We found that serum irisin levels were lower in overweight subjects. Moreover, serum irisin levels were inversely correlated with adverse metabolic parameters including WC, WHR, creatinine, HOMA-IR and fasting insulin, suggesting that irisin may play a role in obesity related insulin resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-019-0479-8","type":"journal-article","created":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T13:02:42Z","timestamp":1577451762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The association of circulating irisin with metabolic risk factors in Chinese adults: a cross-sectional community-based study"],"prefix":"10.1186","volume":"19","author":[{"given":"Lizhi","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhen","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Cong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Jobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5395-3660","authenticated-orcid":false,"given":"Nanwei","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,27]]},"reference":[{"issue":"7","key":"479_CR1","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/iub.1511","volume":"68","author":"A Shoukry","year":"2016","unstructured":"Shoukry A, Shalaby SM, El-Arabi Bdeer S, Mahmoud AA, Mousa MM, Khalifa A. Circulating serum irisin levels in obesity and type 2 diabetes mellitus. IUBMB Life. 2016;68(7):544\u201356.","journal-title":"IUBMB Life"},{"issue":"1","key":"479_CR2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1001\/jama.289.1.76","volume":"289","author":"AH Mokdad","year":"2003","unstructured":"Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. Jama. 2003;289(1):76\u20139.","journal-title":"Jama"},{"issue":"7","key":"479_CR3","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1172\/JCI29069","volume":"116","author":"SE Shoelson","year":"2006","unstructured":"Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793\u2013801.","journal-title":"J Clin Invest"},{"issue":"8","key":"479_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrendo.2012.49","volume":"8","author":"BK Pedersen","year":"2012","unstructured":"Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8(8):457\u201365.","journal-title":"Nat Rev Endocrinol"},{"key":"479_CR5","doi-asserted-by":"publisher","first-page":"7816806","DOI":"10.1155\/2018\/7816806","volume":"2018","author":"IY Martinez Munoz","year":"2018","unstructured":"Martinez Munoz IY, Camarillo Romero EDS, Garduno Garcia JJ. Irisin a novel metabolic biomarker: present knowledge and future directions. Int J Endocrinol. 2018;2018:7816806.","journal-title":"Int J Endocrinol"},{"key":"479_CR6","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fendo.2019.00524","volume":"10","author":"LI Arhire","year":"2019","unstructured":"Arhire LI, Mihalache L, Covasa M. Irisin: a Hope in understanding and managing obesity and metabolic syndrome. Front Endocrinol. 2019;10:524.","journal-title":"Front Endocrinol"},{"issue":"7382","key":"479_CR7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nature10777","volume":"481","author":"P Bostrom","year":"2012","unstructured":"Bostrom P, Wu J, Jedrychowski MP, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463\u20138.","journal-title":"Nature"},{"issue":"6","key":"479_CR8","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nrendo.2016.221","volume":"13","author":"N Perakakis","year":"2017","unstructured":"Perakakis N, Triantafyllou GA, Fernandez-Real JM, et al. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017;13(6):324\u201337.","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"479_CR9","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.metabol.2012.09.002","volume":"61","author":"JY Huh","year":"2012","unstructured":"Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans: I. predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metab Clin Exp. 2012;61(12):1725\u201338.","journal-title":"Metab Clin Exp"},{"issue":"12","key":"479_CR10","doi-asserted-by":"publisher","first-page":"4899","DOI":"10.1210\/jc.2013-2373","volume":"98","author":"KH Park","year":"2013","unstructured":"Park KH, Zaichenko L, Brinkoetter M, et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab. 2013;98(12):4899\u2013907.","journal-title":"J Clin Endocrinol Metab"},{"key":"479_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.peptides.2012.11.014","volume":"39","author":"A Stengel","year":"2013","unstructured":"Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity--correlation with body mass index. Peptides. 2013;39:125\u201330.","journal-title":"Peptides"},{"issue":"4","key":"479_CR12","doi-asserted-by":"publisher","first-page":"e0124100","DOI":"10.1371\/journal.pone.0124100","volume":"10","author":"M Moreno","year":"2015","unstructured":"Moreno M, Moreno-Navarrete JM, Serrano M, et al. Circulating irisin levels are positively associated with metabolic risk factors in sedentary subjects. PLoS One. 2015;10(4):e0124100.","journal-title":"PLoS One"},{"issue":"1","key":"479_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12902-016-0123-9","volume":"16","author":"X Shi","year":"2016","unstructured":"Shi X, Lin M, Liu C, et al. Elevated circulating irisin is associated with lower risk of insulin resistance: association and path analyses of obese Chinese adults. BMC Endocr Disord. 2016;16(1):44.","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"479_CR14","doi-asserted-by":"publisher","first-page":"E769","DOI":"10.1210\/jc.2012-2749","volume":"98","author":"JM Moreno-Navarrete","year":"2013","unstructured":"Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab. 2013;98(4):E769\u201378.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"479_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/cen.13013","volume":"85","author":"L Tang","year":"2016","unstructured":"Tang L, Zhang F, Tong N. The association of visceral adipose tissue and subcutaneous adipose tissue with metabolic risk factors in a large population of Chinese adults. Clin Endocrinol. 2016;85(1):46\u201353.","journal-title":"Clin Endocrinol"},{"key":"479_CR16","doi-asserted-by":"crossref","unstructured":"WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet (London, England). 2004;363(9403):157\u2013163.","DOI":"10.1016\/S0140-6736(03)15268-3"},{"issue":"7","key":"479_CR17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412\u20139.","journal-title":"Diabetologia."},{"issue":"7","key":"479_CR18","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1210\/jcem.85.7.6661","volume":"85","author":"A Katz","year":"2000","unstructured":"Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85(7):2402\u201310.","journal-title":"J Clin Endocrinol Metab"},{"issue":"0035","key":"479_CR19","first-page":"881","volume":"63","author":"BW Liu","year":"2017","unstructured":"Liu BW, Yin FZ, Qi XM, Fan DM, Zhang Y. The Levels of Serum Irisin as a Predictor of Insulin Resistance in Han Chinese Adults with Metabolically Healthy Obesity. Clin Lab. 2017;63(0035):881\u20136.","journal-title":"Clin Lab"},{"issue":"4","key":"479_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1152\/advan.00052.2006","volume":"30","author":"H Liang","year":"2006","unstructured":"Liang H, Ward WF. PGC-1alpha: a key regulator of energy metabolism. Adv Physiol Educ. 2006;30(4):145\u201351.","journal-title":"Adv Physiol Educ"},{"issue":"7","key":"479_CR21","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s00125-006-0268-6","volume":"49","author":"S Soyal","year":"2006","unstructured":"Soyal S, Krempler F, Oberkofler H, Patsch W. PGC-1alpha: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes. Diabetologia. 2006;49(7):1477\u201388.","journal-title":"Diabetologia"},{"issue":"3","key":"479_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267\u201373.","journal-title":"Nat Genet"},{"issue":"5","key":"479_CR23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00592-014-0576-0","volume":"51","author":"G Sesti","year":"2014","unstructured":"Sesti G, Andreozzi F, Fiorentino TV, et al. High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects. Acta Diabetol. 2014;51(5):705\u201313.","journal-title":"Acta Diabetol"},{"issue":"4","key":"479_CR24","doi-asserted-by":"publisher","first-page":"e94235","DOI":"10.1371\/journal.pone.0094235","volume":"9","author":"B Yan","year":"2014","unstructured":"Yan B, Shi X, Zhang H, et al. Association of serum irisin with metabolic syndrome in obese Chinese adults. PLoS One. 2014;9(4):e94235.","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"479_CR25","doi-asserted-by":"publisher","first-page":"S467","DOI":"10.1016\/j.dsx.2017.03.037","volume":"11","author":"M Shanaki","year":"2017","unstructured":"Shanaki M, Moradi N, Emamgholipour S, Fadaei R, Poustchi H. Lower circulating irisin is associated with nonalcoholic fatty liver disease and type 2 diabetes. Diabetes & metabolic syndrome. 2017;11(Suppl 1):S467\u201372.","journal-title":"Diabetes & metabolic syndrome"},{"issue":"2","key":"479_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/eci.12196","volume":"44","author":"NM Al-Daghri","year":"2014","unstructured":"Al-Daghri NM, Alkharfy KM, Rahman S, et al. Irisin as a predictor of glucose metabolism in children: sexually dimorphic effects. Eur J Clin Investig. 2014;44(2):119\u201324.","journal-title":"Eur J Clin Investig"},{"issue":"5","key":"479_CR27","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1210\/jc.2015-1208","volume":"100","author":"T Reinehr","year":"2015","unstructured":"Reinehr T, Elfers C, Lass N, Roth CL. Irisin and its relation to insulin resistance and puberty in obese children: a longitudinal analysis. J Clin Endocrinol Metab. May 2015;100(5):2123\u201330.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"479_CR28","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.metabol.2016.02.006","volume":"65","author":"S Qiu","year":"2016","unstructured":"Qiu S, Cai X, Yin H, et al. Association between circulating irisin and insulin resistance in non-diabetic adults: a meta-analysis. Metab Clin Exp. 2016;65(6):825\u201334.","journal-title":"Metab Clin Exp"},{"issue":"1","key":"479_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/enr-2017-0001","volume":"51","author":"I Ates","year":"2017","unstructured":"Ates I, Arikan MF, Erdogan K, et al. Factors associated with increased irisin levels in the type 1 diabetes mellitus. Endocr Regul. 2017;51(1):1\u20137.","journal-title":"Endocr Regul"},{"issue":"11","key":"479_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1055\/a-0748-6170","volume":"50","author":"A Tentolouris","year":"2018","unstructured":"Tentolouris A, Eleftheriadou I, Tsilingiris D, et al. Plasma Irisin levels in subjects with type 1 diabetes: comparison with healthy controls. Horm Metab Res. 2018;50(11):803\u201310.","journal-title":"Horm Metab Res"},{"issue":"4","key":"479_CR31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jdiacomp.2013.03.002","volume":"27","author":"JJ Liu","year":"2013","unstructured":"Liu JJ, Wong MD, Toy WC, et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complicat. 2013;27(4):365\u20139.","journal-title":"J Diabetes Complicat"},{"issue":"10","key":"479_CR32","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1055\/s-0042-108730","volume":"48","author":"XL Du","year":"2016","unstructured":"Du XL, Jiang WX, Lv ZT. Lower circulating Irisin level in patients with diabetes mellitus: a systematic review and meta-analysis. Horm Metab Res. 2016;48(10):644\u201352.","journal-title":"Horm Metab Res"},{"issue":"2","key":"479_CR33","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s12020-017-1476-1","volume":"59","author":"SA Polyzos","year":"2018","unstructured":"Polyzos SA, Anastasilakis AD, Efstathiadou ZA, et al. Irisin in metabolic diseases. Endocrine. 2018;59(2):260\u201374.","journal-title":"Endocrine"},{"issue":"15","key":"479_CR34","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa0808718","volume":"360","author":"WD van Marken Lichtenbelt","year":"2009","unstructured":"van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, et al. Cold-activated brown adipose tissue in healthy men. The New England J Med. 2009;360(15):1500\u20138.","journal-title":"The New England J Med"},{"issue":"4","key":"479_CR35","doi-asserted-by":"publisher","first-page":"e0154319","DOI":"10.1371\/journal.pone.0154319","volume":"11","author":"S Oelmann","year":"2016","unstructured":"Oelmann S, Nauck M, Volzke H, Bahls M, Friedrich N. Circulating Irisin concentrations are associated with a Favourable lipid profile in the general population. PLoS One. 2016;11(4):e0154319.","journal-title":"PLoS One"},{"issue":"3","key":"479_CR36","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/ijo.2017.255","volume":"42","author":"S Buscemi","year":"2018","unstructured":"Buscemi S, Corleo D, Vasto S, et al. Factors associated with circulating concentrations of irisin in the general population cohort of the ABCD study. Int J Obesity (2005). 2018;42(3):398\u2013404.","journal-title":"Int J Obesity (2005)"},{"issue":"5","key":"479_CR37","doi-asserted-by":"publisher","first-page":"e64025","DOI":"10.1371\/journal.pone.0064025","volume":"8","author":"MS Wen","year":"2013","unstructured":"Wen MS, Wang CY, Lin SL, Hung KC. Decrease in irisin in patients with chronic kidney disease. PLoS One. 2013;8(5):e64025.","journal-title":"PLoS One"},{"issue":"4","key":"479_CR38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.4161\/adip.26082","volume":"2","author":"HP Erickson","year":"2013","unstructured":"Erickson HP. Irisin and FNDC5 in retrospect: An exercise hormone or a transmembrane receptor? Adipocyte. 2013;2(4):289\u201393.","journal-title":"Adipocyte"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-019-0479-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12902-019-0479-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-019-0479-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T19:14:27Z","timestamp":1608923667000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-019-0479-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["479"],"URL":"https:\/\/doi.org\/10.1186\/s12902-019-0479-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.13765\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.13765\/v1","asserted-by":"object"}]},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"24 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Medical Ethics Committee of West China Hospital of Sichuan University and was conducted in accordance with the principles of the Declaration of Helsinki II. Written informed consents were obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants provided written informed consent for study data to be published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}